Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2023-12-06 Earnings Release
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated December 6, 2023, titled "TheraVet reports further achievements on its Osteosarcoma Program." It provides an update on operational progress, sales figures, educational programs, clinical studies, and includes a quote from the CEO regarding the success of the 2023 strategy. This format—a brief announcement highlighting key operational and financial milestones for a specific period (2023 achievements)—is characteristic of an Earnings Release (ER), which typically precedes or is separate from the full quarterly/annual report (IR or 10-K). It is not a full financial statement (IR), a transcript (CT), or a formal regulatory filing like a 10-K. Since it announces results/achievements, ER is the most appropriate classification. FY 2023
2023-12-06 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated December 6, 2023, from TheraVet, providing an update on the progress of its osteosarcoma program, including user numbers, conference presentations, educational webinars, clinical case reports, and the launch of a new clinical study. This content structure—a formal announcement detailing operational and clinical progress for a specific period (2023 updates)—is characteristic of an Earnings Release (ER) or a general business update. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate classification is Earnings Release (ER), as it summarizes recent performance and operational milestones, often released around reporting periods.
2023-12-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated November 23, 2023, announcing the launch of a clinical study by TheraVet in collaboration with the University of Florida regarding their product BIOCERA-VET® for canine osteosarcoma. This type of announcement, detailing operational news, partnerships, and study launches, is characteristic of a general corporate update or regulatory filing that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a specific announcement about a clinical development and not a standard financial report, and it doesn't fit into MANG, DIRS, DIV, or CAP, the most appropriate general category for a significant, non-financial corporate update that is not a formal report announcement is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate news releases.
2023-11-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 93% confidence The document is a press release from TheraVet, dated November 23, 2023, announcing the launch of a clinical study evaluating their product BIOCERA-VET® in canine osteosarcoma, conducted by the University of Florida. This type of announcement, detailing new research, product development, or strategic partnerships, does not fit the specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). It is an announcement about company activity and scientific progress. Since it is not a formal regulatory filing (like a DIRS or MRQ) nor a presentation (IP), and it is not a general regulatory announcement (RNS), the most appropriate category for a press release detailing business/scientific updates that don't fit elsewhere is often considered a general Regulatory Filing (RNS) if no better fit exists, or sometimes it can be classified as Investor Presentation (IP) if it were a presentation deck, but here it is a news release. Given the options, and since it is a formal announcement of a business/scientific development, it falls best under the general 'Regulatory Filings' (RNS) as a catch-all for non-standard corporate news releases, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are clearly incorrect. Since it is a news announcement, and not a report itself, RNS is the best fit among the provided codes for a general corporate press release.
2023-11-23 French
Theravet_SA-_Rapport_art_7_198,_7_180,_7_191_&_7_193_executed.pdf
Audit Report / Information Classification · 95% confidence The document is a formal report, specifically titled "RAPPORT D'ÉVALUATION DU COMMISSAIRE AU CONSEIL D'ADMINISTRATION DE LA SOCIÉTÉ THERAVET SA PORTANT SUR LES DONNÉES FINANCIÈRES ET COMPTABLES..." and is issued by an auditor (PwC) concerning financial data within a report from the Board of Directors, referencing specific articles of the Belgian Code des sociétés et des associations (CSA) related to financial reporting and shareholder rights (Articles 7:180, 7:191, 7:193, 7:198). It includes a conclusion from the auditor regarding the financial data and justification for issuing convertible bonds while suppressing pre-emptive rights. It also contains the "RAPPORT SPECIAL DU CONSEIL D'ADMINISTRATION ETABLI CONFORMEMENT AUX ARTICLES 7:198 *juncto* 7:180, 7:191 ET 7:193 DU CODE DES SOCIETES ET DES ASSOCIATIONS". This structure—a detailed report from the Board justifying a corporate action (issuance of convertible bonds/suppression of preference rights) accompanied by a formal evaluation report from an external auditor on the financial aspects—is characteristic of comprehensive regulatory filings concerning capital structure changes or major transactions, often filed alongside or as part of an Annual Report or a specific disclosure document. However, the content is not a standard 10-K (US Annual Report) or a simple Earnings Release (ER). It is a detailed report justifying a specific corporate action (issuance of convertible bonds and removal of pre-emptive rights) and includes an auditor's assurance report on the financial data supporting this action. This aligns closely with the detailed disclosure required for significant corporate actions, which often falls under comprehensive reporting requirements. Given the options, this document is a highly specific, legally mandated report detailing financial justification for a capital change (issuance of convertible bonds and removal of preference rights), accompanied by an auditor's review. It is too detailed to be a simple 'Audit Report' (AR) or 'Capital/Financing Update' (CAP) alone, as it contains the full justification from management and the auditor's assessment. Since it is a comprehensive report detailing financial performance context for a major corporate action, and it is not a standard US 10-K, it best fits the category of a detailed financial disclosure document. In the context of the provided definitions, it most closely resembles a comprehensive report detailing financial and governance aspects related to a major transaction, but none fit perfectly. The presence of the auditor's report on the financial data supporting the Board's action strongly suggests a formal Audit Report/Information (AR) context, even though it's tied to a financing event. If we consider 'AR' as covering standalone audit reports and applied accounting principles, this document is essentially an auditor's report on the financial data supporting the Board's proposal for capital change. Revisiting the definitions: It is a formal report from the auditor (Commissaire) evaluating the financial data in the Board's report regarding a capital operation. This is a specialized Audit/Assurance Report. Therefore, 'AR' (Audit Report / Information) is the most appropriate fit among the choices for a document centered on an external auditor's formal assessment of financial data supporting a corporate action. FY 2023
2023-11-20 French
TheraVet_-_Rapport_spe´cial_CA_OC_executed.pdf
Capital/Financing Update Classification · 98% confidence The document is titled "RAPPORT SPECIAL DU CONSEIL D'ADMINISTRATION ETABLI CONFORMEMENT AUX ARTICLES 7:198 *juncto* 7:180, 7:191 ET 7:193 DU CODE DES SOCIETES ET DES ASSOCIATIONS" (Special Report of the Board of Directors established in accordance with Articles...). The content details a proposal by the Board of Directors to issue convertible bonds (Obligations Convertibles) under authorized capital, outlining the terms, subscription process, conversion mechanism, and pricing. This document is a formal report providing detailed information and justification for a significant corporate financing/capital structure event (issuance of debt convertible into equity). This aligns best with the 'Capital/Financing Update' category (CAP), as it is a detailed report on a financing operation, rather than just a brief announcement (RPA/ER) or a general legal filing (RNS). It is too detailed to be a simple 'Share Issue/Capital Change' (SHA), which usually covers the final execution or simple announcement of a share change, whereas this is a preparatory special report required by corporate law for such a transaction.
2023-11-20 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.